Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS.
Athanasios D AnastasilakisJessica PepeNicola NapoliAndrea PalermoChristos MagopoulosAliya A KhanM Carola ZillikensJean-Jacques BodyPublished in: The Journal of clinical endocrinology and metabolism (2022)
The risk for MRONJ largely depends on the underlying bone disease and the relevant antiresorptive regimen applied. Physicians and dentists should keep in mind that the benefits of antiresorptive therapy far outweigh the risk for MRONJ development.